Clinical Trials Browser

Interventional × Alpelisib × 90 days × Clear all

NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Phase 2 Active not recruiting

Breast Neoplasms, Genetic Diseases, Inborn

NCT05948943 2026-05-12

EPIK-L1

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT04251533 2026-05-11

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT05983159 2026-05-05

TARGET-VM

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT05143229 2026-05-01

ASSET

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT04524000 2026-04-08

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

Advanced Breast Cancer

NCT05038735 2026-04-08

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT05631795 2026-04-07

ALPINIST

Phase 4 Completed

Multiple Endocrine Neoplasia Type 1

NCT04208178 2026-04-02

EPIK-B2

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

NCT04544189 2026-04-02

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Phase 2 Active not recruiting

Recurrence